GSK awards $60,000 for innovation in childhood immunisation

The winners of the 2010 GlaxoSmithKline Childhood Immunisation Awards were announced today at the Public Health Association of Australia's 12th National Immunisation Conference in Adelaide.

18/08/2010

GSK rejects misleading media reporting of its clinical trial activity

GlaxoSmithKline (GSK) Australia today rejected misleading reports in several media outlets over the weekend in relation to its conduct of clinical trials (Sunday Telegraph, Sunday Times, Courier Mail).

23/07/2010

Carbon Dioxide gas leak at GSK’s Port Fairy factory contained.

A carbon dioxide gas leak, caused by a ruptured pipe, within GlaxoSmithKline’s Port Fairy factory occurred this morning but did not affect the health of the community and no one was injured.

16/07/2010

GlaxoSmithKline statement in response to FDA Advisory Committees’ vote on safety of Avandia® (rosiglitazone maleate)

GlaxoSmithKline (GSK) confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the...

15/07/2010

Avandia (rosiglitazone maleate): GSK Australia spokesperson available post FDA Advisory Group Recommendation.

GlaxoSmithKline (GSK) Australia Medical Director, Dr Camilla Chong will be available to speak with Australian journalists about the outcome of the U.S. Food and Drug Administration (FDA) Advisory Committee recommendation in relation to the...

13/07/2010

GSK EU Regulatory Update on Avandia (Rosiglitazone Maleate)

GlaxoSmithKline (GSK) today confirmed that on behalf of the European Medicines Agency (EMA), the Committee for Medicinal Products for Human Use (CHMP) is to review the benefit/risk profile of Avandia (rosiglitazone).

10/07/2010

Data support Avandia (rosiglitazone maleate) cardiovascular safety profile

The U.S. Food and Drug Administration (FDA) today posted a comprehensive review conducted by GlaxoSmithKline (GSK) of the cardiovascular safety data on Avandia® (rosiglitazone maleate).

10/07/2010

GSK rejects conclusions of US Senate Committee on Finance Staff Report on Avandia® (rosiglitazone maleate)

The US Staff Report of the Senate Committee on Finance draws conclusions on the safety of Avandia that are based on analyses that are not consistent with the rigorous scientific evidence supporting the safety of the drug.

29/06/2010

Australians avoid flu shot over fears it will make them sick

Nearly one in five Australians will not get the flu shot this year, because they incorrectly believe it will give them the flu according to the GlaxoSmithKline (GSK) Health Index released today.

10/06/2010

GSK Welcomes PBS Memorandum of Understanding

Industry certainty and better patient access to new medicines to be achieved through the Memorandum of Understanding (MOU) between Medicines Australia and the Commonwealth was welcomed today by GlaxoSmithKline (GSK) Australia.

11/05/2010